Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05333809 |
TitlePembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-04-19 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Disitamab vedotin, Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT05382442 |
TitleA Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-05-19 |
地点
California, United States
中国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT05480306 |
TitlePhase 2 Study of DKN-01 in Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-07-29 |
地点
Arizona, United States
California, United States Florida, United States Louisiana, United States Maryland, United States Missouri, United States New York, United States North Carolina, United States South Carolina, United States South Dakota, United States Tennessee, United States Washington, United States Wisconsin, United States 德国 大韩民国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, DKN-01, FOLFIRI, FOLFOX |
标签
MSS/ MMRp
|
| NCT ID NCT05482516 |
TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers | 阶段
第三阶段
|
Date Added 2022-08-01 |
地点
District of Columbia, United States
New Jersey, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Atezolizumab, Bevacizumab, Avastin, Tecentriq |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05491083 |
TitlePembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | 阶段
第 1 阶段
|
Date Added 2022-08-08 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
尚未招聘
|
药物
Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06300463 |
Title结直肠癌肝转移免疫疗法组合平台研究 | 阶段
第二阶段
|
Date Added 2024-03-08 |
地点
New York, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
AGEN1423, Balstilimab, Botensilimab |
标签
MSS/ MMRp
|
| NCT ID NCT06336902 |
TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2024-03-29 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Balstilimab, Botensilimab |
标签
MSS/ MMRp
|
| NCT ID NCT06152523 |
TitleMonalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer | 阶段
第二阶段
|
Date Added 2023-11-30 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Monalizumab/MEDI5257 |
标签
MSI-H/ MMRd
|
| NCT ID NCT04444622 |
TitleImmunotherapy for Third Line Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2020-06-23 |
地点
Florida, United States
Michigan, United States New Jersey, United States New York, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT05879822 |
Title评估INCB099280对免疫检查点抑制剂无效的特定实体瘤患者的作用的研究 | 阶段
第二阶段
|
Date Added 2023-05-30 |
地点
巴西
中国 格鲁吉亚 希腊 Hungary 新西兰 Romania 南非 Turkey |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
INCB099280 |
标签
MSI-H/ MMRd
|
